Kinase inhibitors in the treatment of immune-mediated disease
Authors:
- Apostolos KontziasAKApostolos Kontzias
- Arian LaurenceALArian Laurence
- Massimo GadinaMGMassimo Gadina
- John J. O’sheaJOJohn J. O’shea
Open Access
- 1 March 2012
- journal article
- Published by H1 Connect in F1000 Medicine Reports
- Vol. 4 (5) , 5
Abstract
Kinase inhibitors in the treatment of immune-mediated diseaseKeywords
This publication has 58 references indexed in Scilit:
- A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritisArthritis Research & Therapy, 2011
- Lestaurtinib Inhibition of the JAK/STAT Signaling Pathway in Hodgkin Lymphoma Inhibits Proliferation and Induces ApoptosisPLOS ONE, 2011
- Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)The Journal of Immunology, 2011
- Deciphering the anticancer mechanisms of sunitinibCancer Biology & Therapy, 2010
- Genetic deficiency of Syk protects mice from autoantibody‐induced arthritisArthritis & Rheumatism, 2010
- CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasmsBlood, 2010
- NSC114792, a novel small molecule identified through structure-based computational database screening, selectively inhibits JAK3Molecular Cancer, 2010
- The PKC inhibitor AEB071 may be a therapeutic option for psoriasisJournal of Clinical Investigation, 2008
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth MachineryCell, 2002